Amendment to the Claims

The following listing of claims will replace all prior versions and listings of claims.

Listing of Claims:

1-22. (Canceled)

23. (Previously Presented) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein consisting of amino acid residues -16 to 498 of SEQ ID NO:10;

(b) a protein consisting of amino acid residues 1 to 498 of SEQ ID NO:10; and,

(c) a protein consisting of the extracellular domain of the FcR-V polypeptide having the amino acid sequence at positions 1 to 343 in SEQ ID NO:10.

24. (Previously Presented) The antibody or fragment thereof of claim 23 that specifically binds protein (a).

25. (Previously Presented) The antibody or fragment thereof of claim 23 that specifically binds protein (b).

26. (Previously Presented) The antibody or fragment thereof of claim 23 that specifically binds protein (c).

27. (Previously Presented) The antibody or fragment thereof of claim 24 that specifically binds protein (b).

28. (Previously Presented) The antibody or fragment thereof of claim 23 which is a human antibody.

29. (Previously Presented) The antibody or fragment thereof of claim 23 which is a monoclonal antibody.

30. (Previously Presented) The antibody or fragment thereof of claim 23 which is a polyclonal antibody.

31. (Previously Presented) The antibody or fragment thereof of claim 23 which is selected from the group consisting of:
(a) a chimeric antibody;
(b) a humanized antibody;
(c) a single chain antibody; and
(d) a Fab fragment.

32. (Previously Presented) The antibody or fragment thereof of claim 23 which is labeled.

33. (Previously Presented) The antibody or fragment thereof of claim 23 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

34. (Previously Presented) The antibody or fragment thereof of claim 23 wherein said antibody or fragment thereof specifically binds to said protein in an Enzyme Linked Immunosorbent Assay (ELISA).

35. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 23.

36. (Previously Presented) A hybridoma that produces the antibody or fragment thereof of claim 23.

37. (Previously Presented) A method of detecting Fc Receptor-V (FcR-V) protein in a biological sample comprising:
(a) contacting the biological sample with the antibody or fragment thereof of claim 23; and

(b) detecting the FcR-V protein in the biological sample bound to the antibody or fragment thereof of claim 23.

38. (Previously Presented) The method of claim 37 wherein the antibody or fragment thereof is a monoclonal antibody.

39. (Previously Presented) The method of claim 37 wherein the antibody or fragment thereof is a polyclonal antibody.

40. (Previously Presented) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209100;

(b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209100; and,

(c) a protein consisting of the extracellular domain of the FcR-V polypeptide encoded by the FcR-V cDNA in the FcR-V plasmid contained in ATCC Deposit Number 209100.

41. (Previously Presented) The antibody or fragment thereof of claim 40 that specifically binds protein (a).

42. (Previously Presented) The antibody or fragment thereof of claim 40 that specifically binds protein (b).

43. (Previously Presented) The antibody or fragment thereof of claim 40 that specifically binds protein (c).

44. (Previously Presented) The antibody or fragment thereof of claim 41 that specifically binds protein (b).

45. (Previously Presented) The antibody or fragment thereof of claim 40 which is a human antibody.

46. (Previously Presented) The antibody or fragment thereof of claim 40 which is a monoclonal antibody.

47. (Previously Presented) The antibody or fragment thereof of claim 40 which is a polyclonal antibody.

48. (Previously Presented) The antibody or fragment thereof of claim 40 which is selected from the group consisting of:
(a) a chimeric antibody;
(b) a humanized antibody;
(c) a single chain antibody; and
(d) a Fab fragment.

49. (Previously Presented) The antibody or fragment thereof of claim 40 which is labeled.

50. (Previously Presented) The antibody or fragment thereof of claim 40 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

51. (Previously Presented) The antibody or fragment thereof of claim 40 wherein said antibody or fragment thereof specifically binds to said protein in an Enzyme Linked Immunosorbent Assay (ELISA).

52. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 40.

53. (Previously Presented) A hybridoma that produces the antibody or fragment thereof of claim 40.

54. (Previously Presented) A method of detecting Fc Receptor-V (FcR-V) protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 40; and

(b) detecting the FcR-V protein in the biological sample bound to the antibody or fragment thereof of claim 40.

55. (Previously Presented) The method of claim 54 wherein the antibody or fragment thereof is a monoclonal antibody.

56. (Previously Presented) The method of claim 54 wherein the antibody or fragment thereof is a polyclonal antibody.

57. (Previously Presented) An isolated antibody or fragment thereof that specifically binds a FcR-V protein expressed on the surface of cells in a cell culture wherein the cells in said culture comprise a polynucleotide encoding amino acids 1 to 498 of SEQ ID NO:10 operably associated with a regulatory sequence that controls the expression of said polynucleotide .

58. (Previously Presented) The antibody or fragment thereof of claim 57 which is a human antibody.

59. (Previously Presented) The antibody or fragment thereof of claim 57 which is a monoclonal antibody.

60. (Previously Presented) The antibody or fragment thereof of claim 57 which is a polyclonal antibody.

61. (Previously Presented) The antibody or fragment thereof of claim 57 which is selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

62. (Previously Presented) The antibody or fragment thereof of claim 57 which is labeled.

63. (Previously Presented) The antibody or fragment thereof of claim 57 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

64. (Previously Presented) The antibody or fragment thereof of claim 57 wherein said antibody or fragment thereof specifically binds to said protein in an Enzyme Linked Immunosorbent Assay (ELISA).

65. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 57.

66. (Previously Presented) A hybridoma that produces the antibody or fragment thereof of claim 57.

67. (Previously Presented) A method of detecting Fc Receptor-V (FcR-V) protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 57; and

(b) detecting the FcR-V protein in the biological sample bound to the antibody or fragment thereof of claim 57.

68. (Previously Presented) The method of claim 67 wherein the antibody or fragment thereof is a monoclonal antibody.

69. (Previously Presented) The method of claim 67 wherein the antibody or fragment thereof is a polyclonal antibody.

70. (Previously Presented) An isolated antibody or fragment thereof that specifically binds a FcR-V protein expressed on the surface of cells in a cell culture wherein the cells in said culture comprise the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209100 operably associated with a regulatory sequence that controls the expression of said polynucleotide .

71. (Previously Presented) The antibody or fragment thereof of claim 70 which is a human antibody.

72. (Previously Presented) The antibody or fragment thereof of claim 70 which is a monoclonal antibody.

73. (Previously Presented) The antibody or fragment thereof of claim 70 which is a polyclonal antibody.

74. (Previously Presented) The antibody or fragment thereof of claim 70 which is selected from the group consisting of:

(a) a chimeric antibody;

(b) a humanized antibody;

(c) a single chain antibody; and

(d) a Fab fragment.

75. (Previously Presented) The antibody or fragment thereof of claim 70 which is labeled.

76. (Previously Presented) The antibody or fragment thereof of claim 70 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

77. (Previously Presented) The antibody or fragment thereof of claim 70 wherein said antibody or fragment thereof specifically binds to said protein in an Enzyme Linked Immunosorbent Assay (ELISA).

78. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 70.

79. (Previously Presented) A hybridoma that produces the antibody or fragment thereof of claim 70.

80. (Previously Presented) A method of detecting Fc Receptor-V (FcR-V) protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 70; and

(b) detecting the FcR-V protein in the biological sample bound to the antibody or fragment thereof of claim 70.

81. (Previously Presented) The method of claim 80 wherein the antibody or fragment thereof is a monoclonal antibody.

82. (Previously Presented) The method of claim 80 wherein the antibody or fragment thereof is a polyclonal antibody.